AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Satellite phone (satphone) – a portable wireless telephone similar to a cell phone, connected to the telephone network through a radio link to an orbiting communications satellite instead of through cell towers. They are more expensive than cell phones; but their advantage is that, unlike a cell phone which is limited to areas covered by cell towers, satphones can be used over most or all of the geographical area of the Earth. In order for the phone to communicate with a satellite using a small omnidirectional antenna, first-generation systems use satellites in low Earth orbit, about 400–700 miles (640–1,100 km) above the surface. With an orbital period of about 100 minutes, a satellite can only be in view of a phone for about 4 – 15 minutes, so the call is "handed off" to another satellite when one passes beyond the local horizon. Therefore, large numbers of satellites, about 40 to 70, are required to ensure that at least one satellite is in view continuously from each point on Earth. Other satphone systems use satellites in geostationary orbit in which only a few satellites are needed, but these cannot be used at high latitudes because of terrestrial interference. Cordless phone – a landline telephone in which the handset is portable and communicates with the rest of the phone by a short-range full duplex radio link, instead of being attached by a cord. Both the handset and the base station have low-power radio transceivers that handle the short-range bidirectional radio link. As of 2022, cordless phones in most nations use the DECT transmission standard.
probe-set A collection of two or more probes designed to measure a single molecular species, such as a collection of oligonucleotides designed to hybridize to various parts of the mRNA transcripts generated from a single gene.
=== Fasted state === When fasting, the activation of lipolysis provides fatty acids as the preferred fuel source for respiration. In the liver β-oxidation of fatty acids fulfills the local energy needs and may lead to ketogenesis (creating ketone bodies out of fatty acids.) The ketone bodies are then used to meet the demands of tissues other than the liver. This inhibition of glucose oxidation at the level of pyruvate dehydrogenase preserves pyruvate and lactate, both of which are gluconeogenic precursors.
Sources: en.wikipedia.org
21 April – Mark Menzies quits the Conservative Party and says he will stand down from Parliament at the next election. Robin Swann, who is the perspective Ulster Unionist candidate for South Antrim, announces he will step down from his post as Northern Ireland's Health Minister once the general election campaign begins. 22 April – Parliament passes the Safety of Rwanda Bill, with plans to deport the first asylum seekers to Kigali in July. Two men, including a parliamentary researcher, are charged with spying for China after providing information that could be "useful to an enemy". Conservative councillor Richard Solesbury-Timms, who represents Middleton Cheney on West Northamptonshire Council, leaves the party to sit as an independent citing the party's dealing with allegations against the council leader. 23 April – Patrick Harvie says he will resign as co-leader of the Scottish Greens if the party votes to end its coalition agreement with the SNP. Alliance Party MLA Patrick Brown resigns his South Down seat in the Northern Ireland Assembly, citing personal reasons for doing so. 24 April – Rishi Sunak vows to increase UK defence spending to 2.5% of GDP by 2030. Labour unveils its plans for improvements to train services, which include automatic refunds for delays, a "best price" guarantee and improved internet coverage. Jeffrey Donaldson appears at Newry Magistrates' Court to face charges of historic child abuse. Johnny Timpson, the UK's inaugural disability ambassador, resigns over the UK government's policy of clawing back benefit overpayment.
Plutonium (specifically, plutonium-238) was first produced, isolated, and then chemically identified between December 1940 and February 1941 by Glenn T. Seaborg, Edwin McMillan, Emilio Segrè, Joseph W. Kennedy, and Arthur Wahl by deuteron bombardment of uranium in the 60-inch (150 cm) cyclotron at the Berkeley Radiation Laboratory at the University of California, Berkeley. Neptunium-238 was created directly by the bombardment but decayed by beta emission with a half-life of a little over two days, which indicated the formation of element 94. The first bombardment took place on December 14, 1940, and the new element was first identified through oxidation on the night of February 23–24, 1941. A paper documenting the discovery was prepared by the team and sent to the journal Physical Review in March 1941, but publication was delayed until a year after the end of World War II due to security concerns. At the Cavendish Laboratory in Cambridge, Egon Bretscher and Norman Feather realized that a slow neutron reactor fuelled with uranium would theoretically produce substantial amounts of plutonium-239 as a by-product. They calculated that element 94 would be fissile, and had the added advantage of being chemically different from uranium, and could easily be separated from it. McMillan had recently named the first transuranic element neptunium after the planet Neptune, and suggested that element 94, being the next element in the series, be named for what was then considered the next planet, Pluto.
Wallace, following on earlier work by de Candolle, Humboldt and Darwin, made major contributions to zoogeography. Because of his interest in the transmutation hypothesis, he paid particular attention to the geographical distribution of closely allied species during his field work first in South America and then in the Malay Archipelago. While in the archipelago he identified the Wallace line, which runs through the Spice Islands dividing the fauna of the archipelago between an Asian zone and a New Guinea/Australian zone. His key question, as to why the fauna of islands with such similar climates should be so different, could only be answered by considering their origin. In 1876 he wrote The Geographical Distribution of Animals, which was the standard reference work for over half a century, and a sequel, Island Life, in 1880 that focused on island biogeography. He extended the six-zone system developed by Philip Sclater for describing the geographical distribution of birds to animals of all kinds. His method of tabulating data on animal groups in geographic zones highlighted the discontinuities; and his appreciation of evolution allowed him to propose rational explanations, which had not been done before.
The joint petition denounced the Ba'athist regime for inflicting "unimaginable physical and mental pain and suffering" as a deliberate strategy to collectively punish the Syrian population. In a separate statement, Dutch Foreign Ministry accused Bashar al-Assad of committing severe human rights violations, war crimes and inhumane tactics against the Syrian people "on a grand scale". The joint proceedings were after repeated Russian vetoes in the UN Security Council that blocked efforts to prosecute Bashar al-Assad over war crimes in International Criminal Court. In September 2026, former Adra Prison director Samir Alsheikh was sentenced to 60 years in federal prison in the United States. He was previously convicted in March 2026 of torture and conspiracy to commit torture while he headed the prison from 2005 to 2008.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.